Literature DB >> 8194903

Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7.

R Stein1, A Basu, D M Goldenberg, K O Lloyd, M J Mattes.   

Abstract

Cluster 13 was defined by 2 independently derived murine monoclonal antibodies (MAbs), RS7 (IgG1) and MR54 (IgG2a), which were raised against human squamous-cell carcinoma of the lung and a human ovarian-carcinoma cell line, respectively. Immunologic and biochemical evidence demonstrated that RS7 and MR54, as well as 2 additional MAbs, MR6 (IgG2a) and MR23 (IgG1), generated in the same fusion as MR54, recognize the same antigen, a 46- to 48-kDa glycoprotein. Evaluation of the expression of antigen on the surface of tumor cell lines, Western blotting analyses, competitive binding studies, and double-determinant ELISA assays, support this conclusion. Two distinct epitopes are defined by these MAbs. In order to further characterize this antigen, amino-acid-sequence analyses were performed on peptides derived from antigen purified by affinity chromatography with MAb RS7. The sequence data obtained from 2 peptides, which were independently generated by CNBr cleavage and trypsin digestion respectively indicated identity to GA733-1. The GA733-1 genomic DNA sequence predicted a type-1 membrane protein of 35 kDa, with 4 potential N-linked glycosylation sites. The GA733-1 protein product has not been identified previously, and MAbs to this tumor-associated antigen were not previously known.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8194903     DOI: 10.1002/ijc.2910570721

Source DB:  PubMed          Journal:  Int J Cancer Suppl        ISSN: 0898-6924


  5 in total

1.  Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.

Authors:  Allyson J Ocean; Kenneth L Pennington; Michael J Guarino; Arif Sheikh; Tanios Bekaii-Saab; Aldo N Serafini; Daniel Lee; Max W Sung; Seza A Gulec; Stanley J Goldsmith; Timothy Manzone; Michael Holt; Bert H O'Neil; Nathan Hall; Alberto J Montero; John Kauh; David V Gold; Heather Horne; William A Wegener; David M Goldenberg
Journal:  Cancer       Date:  2012-05-08       Impact factor: 6.860

2.  Pretargeted molecular imaging and radioimmunotherapy.

Authors:  David M Goldenberg; Chien-Hsing Chang; Edmund A Rossi; William J; Robert M Sharkey
Journal:  Theranostics       Date:  2012-05-17       Impact factor: 11.556

3.  Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Authors:  David M Goldenberg; Thomas M Cardillo; Serengulam V Govindan; Edmund A Rossi; Robert M Sharkey
Journal:  Oncotarget       Date:  2015-09-08

4.  The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer.

Authors:  Yuan Mao; Xiaoying Wang; Feng Zheng; Changjun Wang; Qi Tang; Xiaojun Tang; Ning Xu; Huiling Zhang; Dawei Zhang; Lin Xiong; Jie Liang; Jin Zhu
Journal:  Oncotarget       Date:  2016-04-26

Review 5.  The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.

Authors:  David M Goldenberg; Rhona Stein; Robert M Sharkey
Journal:  Oncotarget       Date:  2018-06-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.